Quilter Plc Sells 3,731 Shares of Stryker Corporation $SYK

Quilter Plc trimmed its position in shares of Stryker Corporation (NYSE:SYK) by 3.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 94,248 shares of the medical technology company’s stock after selling 3,731 shares during the quarter. Quilter Plc’s holdings in Stryker were worth $33,125,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cooke Wealth Management LLC acquired a new stake in shares of Stryker in the 4th quarter worth about $4,744,000. Buffalo Business & Estate Services Ltd. acquired a new position in Stryker during the 4th quarter valued at about $714,000. Runnymede Capital Advisors Inc. bought a new stake in Stryker during the 4th quarter worth approximately $3,253,000. Sowell Financial Services LLC raised its stake in shares of Stryker by 2.0% in the fourth quarter. Sowell Financial Services LLC now owns 1,669 shares of the medical technology company’s stock worth $587,000 after purchasing an additional 33 shares during the last quarter. Finally, Stonebridge Financial Group LLC raised its stake in shares of Stryker by 4.0% in the fourth quarter. Stonebridge Financial Group LLC now owns 13,283 shares of the medical technology company’s stock worth $4,668,000 after purchasing an additional 506 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.0%

Shares of NYSE SYK opened at $331.48 on Monday. Stryker Corporation has a 1 year low of $319.32 and a 1 year high of $404.87. The stock has a market cap of $126.95 billion, a P/E ratio of 39.46, a price-to-earnings-growth ratio of 1.94 and a beta of 0.92. The firm has a 50-day moving average of $357.10 and a 200 day moving average of $361.76. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.01 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 41.90%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on SYK shares. UBS Group cut their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. BTIG Research lifted their price objective on shares of Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Citizens Jmp upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price for the company in a research note on Friday, December 19th. Piper Sandler restated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Finally, Barclays reiterated an “overweight” rating and set a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $427.50.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.